In Vitro Modulator Responsiveness of 655 CFTR Variants Found in People With CF
Bihler, H.; Sivachenko, A.; Millen, L.; Bhatt, P.; Thakerar Patel, A.; Chin, J.; Bailey, V.; Musisi, I.; LaPan, A.; Allaire, N. E.; Conte, J.; Simon, N. R.; Magaret, A. S.; Raraigh, K. S.; Cutting, G. R.; Skach, W. R.; Bridges, R. J.; Thomas, P. J.; Mense, M.
Show abstract
BackgroundIn 2017, the US Food and Drug Administration initiated expansion of drug labels for the treatment of cystic fibrosis (CF) to include CF transmembrane conductance regulator (CFTR) gene variants based on in vitro functional studies. This study aims to identify CFTR variants that result in increased chloride (Cl-) transport function by the CFTR protein after treatment with the CFTR-modulator combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA). These data may benefit people with CF (pwCF) who are not currently eligible for modulator therapies. MethodsPlasmid DNA encoding 655 CFTR variants and wild-type (WT) CFTR were transfected into Fisher Rat Thyroid cells that do not natively express CFTR. After 24 hours of incubation with control or TEZ and ELX, and acute addition of IVA, CFTR function was assessed using the transepithelial current clamp conductance assay. Each variants baseline activity, responsiveness to IVA alone, and responsiveness to the TEZ/ELX/IVA combination were measured in three different laboratories. Western blots were conducted to evaluate CFTR protein maturation and complement the functional data. Results and Conclusions253 variants not currently approved for CFTR modulator therapy showed low baseline activity (<10% of normal CFTR Cl- transport activity). For 152 of these variants, treatment with ELX/TEZ/IVA improved the Cl- transport activity by [≥]10% of normal CFTR function, which is suggestive of clinical benefit. ELX/TEZ/IVA increased CFTR function by [≥]10 percentage points for an additional 140 unapproved variants with [≥]10% but <50% of normal CFTR function at baseline. These findings significantly expand the number of rare CFTR variants for which ELX/TEZ/IVA treatment should result in clinical benefit.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Dynamics of abdominal symptoms during the start of a new therapy with Elexacaftor/Tezacaftor/Ivacaftor using the novel CFAbd-day2day questionnaire 91%
- Electrophysiological classification of CACNA1G gene variants associated with neurodevelopmental and neurological disorders 90%
- Species-specific effects of cation channel TRPM4 small-molecule inhibitors 90%
Similar papers in this journal
- FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis Genotypes 95%
- Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10kb C-to-T splicing mutation 94%
- TLN468 changes the pattern of tRNA used to readthrough premature termination codons in CFTR 93%
Similar papers in this journal
- Benchmarking AlphaMissense Pathogenicity Predictions Against Cystic Fibrosis Variants 94%
- HDAC6 inhibitor ACY-1083 shows lung epithelial protective features in COPD 91%
- Modeling Cystic Fibrosis Patient Prognosis: Nomograms To Predict Lung Transplantation And Survival Prior To Highly Effective Modulator Therapy 90%
Similar papers in this journal
- Modulation of cAMP metabolism for CFTR potentiation in human airway epithelial cells 94%
- Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 Spike protein 93%
- Reflection confocal microscopy for quantitative assessment of airway surface liquid dysregulation and pharmacological rescue in cystic fibrosis under near-physiological conditions 92%
Similar papers in this journal
- Redefining hypo- and hyper-responding phenotypes of CFTR mutants for understanding and therapy. 95%
- Full Rescue of F508del-CFTR Processing and Function by CFTR Modulators can be Achieved by Removal of Two Unique Regulatory Regions 94%
- Drug repurposing for Cystic Fibrosis: identification of drugs that induce CFTR-independent fluid secretion in nasal organoids 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.